PL120131 acetate
Based on 1 Customer Validation
PL120131 acetate is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 acetate rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 acetate can be used in research related to breast cancer and various malignant tumors.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.82%
- Formule: C62H105N19O18·xC2H4O2
- Masse moléculaire:1404.61 (free base)
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
Description
In Vitro
PL120131 acetate (32.0-33.4 μM) rescues Jurkat cells from PD-L1-induced apoptosis, reducing apoptotic signals by 25% with an IC50 of 32.0 μM (Annexin V) and 33.4 μM (Caspase 3/7)[2].
PL120131 acetate (11.6 μM; 24 h) rescues primary mouse T-cells from apoptosis in 4T1 co-cultures, increases 4T1 cell death, and induces a significant, dose-dependent increase in Granzyme B production in CD3+/CD8+ T-cells[2].
PL120131 acetate (0.2-12.5 μg/mL; 24 h) induces dose-dependent increases in IFNγ and dose-dependent decreases in IL-12p70 and IL-10 in co-cultures of primary mouse lymphocytes and 4T1 cells, indicating activated T-cell function[2].
PL120131 acetate (30 μM; 30 min (Jurkat pre-treatment); 24 h (co-culture in microfluidics chip)) enables Jurkat cells to infiltrate a 3D MDA-MB-231 tumor environment, induce greater tumor cell death, and maintain higher Jurkat cell viability than anti-PD-1 antibody treatment[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 1404.61 (free base)
-
Formule C62H105N19O18·xC2H4O2
-
Color White to off-white
-
Sequence
Ac-Gly-Ala-Asp-Tyr-Lys-Arg-Ile-Thr-Val-Lys-Val-Asn-NH2
-
Sequence Shortening
Ac-GADYKRITVKVN-NH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
In Vitro:
H2O : 5 mg/mL (Need ultrasonic)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[2]. Boohaker R J, et al. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction[J]. Cancer letters, 2018, 434: 11-21. [Content Brief]
[4]. Sun M, et al. Fibroblast Activation Protein-α Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy. Small. 2022;18(9):e2106296. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)